Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.49 |
| ▸ | TACR1 | P25103 | 4/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1936274 | 0.99 | SLC6A4 (0.48) | SLC6A4TACR1PRMT5WDR77SLC6A2 | |
| SCHEMBL1936986 | 0.87 | SLC6A4 (0.47) | SLC6A4TACR1PRMT5WDR77SLC6A2 | |
| SCHEMBL1937045 | 0.85 | SLC6A4 (0.47) | SLC6A4TACR1PRMT5WDR77SLC6A2 | |
| Hydrochloric Acid SCHEMBL1936328 | 0.84 | SLC6A4 (0.47) | SLC6A4TACR1PRMT5WDR77SLC6A2 | |
| SCHEMBL2397352 | 0.83 | OPRK1 (0.42) | SLC6A4SLC6A2SLC6A3KCNH2CHRM3 | |
| SCHEMBL2394314 | 0.83 | SLC6A4 (0.46) | SLC6A4TACR1PRMT5WDR77SLC6A2 | |
| Fumaric Acid SCHEMBL1937621 | 0.81 | SLC6A4 (0.43) | SLC6A4TACR1PRMT5WDR77SLC6A2 | |
| Fumaric Acid SCHEMBL1934781 | 0.77 | CCR2 (0.39) | SLC6A4SLC6A2SLC6A3CHRM2CHRM3 | |
| Fumaric Acid SCHEMBL1935056 | 0.77 | SLC6A4 (0.42) | SLC6A4TACR1PRMT5WDR77SLC6A2 | |
| SCHEMBL3039337 | 0.77 | PDK1 (0.48) | SLC6A4TACR1PRMT5WDR77SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212997-A1 | PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-09-01 | — | — | US | claimed |
| EP-2331505-A2 | PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2011-06-15 | — | — | EP | claimed |
| WO-2010023197-A2 | NOVEL PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-03-04 | — | — | WO | claimed |
| US-20110212997-A1 | PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-09-01 | — | — | US | disclosed |
| EP-2331505-A2 | PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010023197-A2 | NOVEL PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212997-A1 | PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | SLC6A4 4/4885TACR1 131/4885PRMT5 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.